FDA Clears CT-Based AI Software for Enhanced Detection of Usual Interstitial Pneumonia
The IQ-UIP AI software may bolster computed tomography diagnosis of usual interstitial pneumonia (UIP), which is reportedly misdiagnosed in over 50 percent of cases.
The Food and Drug Administration (FDA) has granted 510(k) clearance for IQ-UIP, an artificial intelligence (AI)-powered software for enhancing computed tomography (CT) diagnosis of usual interstitial pneumonia (UIP).
Leveraging deep learning technology, IQ-UIP provides automated analysis of conventional CT scans with rapid detection of UIP patterns such as honeycombing and subpleural fibrosis, according to 4DMedical, the developer of IQ-UIP.
In addition to facilitating improved detection of usual interstitial pneumonia (UIP) on standard CT scans, 4DMedical says the newly FDA-cleared AI software IQ-UIP provides automated referral workflows for specialists who treat UIP. (Image courtesy of RadiologyinThai.com )
Emphasizing that more than 50 percent of UIP is initially misdiagnosed, 4DMedical noted the condition’s non-specific symptomatology may mimic other conditions such as asthma and chronic obstructive pulmonary disease (COPD).
In addition to a rapid diagnosis of UIP, which is characterized by chronic inflammation and progressive lung fibrosis, 4DMedical said IQ-UIP provides automated referral workflows for specialists, facilitating timely care for a condition that has a median survival of one to two years after diagnosis.
Recent Videos
Related Content
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Article
Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025Article
The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025Article
The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
